(Q30358735)

20 June 2017

title

Antiviral management of seasonal and pandemic influenza. (English)

1 reference

20 June 2017

0 references

1

Frederick G Hayden

1 reference

20 June 2017

Andrew T Pavia

2

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Infectious Diseases

20 June 2017

published in

1 reference

20 June 2017

volume

194 Suppl 2

1 reference

20 June 2017

page(s)

S119-26

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

20 June 2017

cites work

1 reference

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

21 January 2018

1 reference

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

21 January 2018

1 reference

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study

21 January 2018

1 reference

Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population.

21 January 2018

1 reference

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

21 January 2018

1 reference

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

21 January 2018

1 reference

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors

21 January 2018

1 reference

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

Antivirals for influenza in healthy adults: systematic review.

21 January 2018

1 reference

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

21 January 2018

1 reference

Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.

21 January 2018

1 reference

Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir

21 January 2018

1 reference

Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza

21 January 2018

1 reference

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae

21 January 2018

1 reference

Strategies for containing an emerging influenza pandemic in Southeast Asia

21 January 2018

1 reference

Containing pandemic influenza at the source.

21 January 2018

1 reference

Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

21 January 2018

1 reference

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

21 January 2018

1 reference

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

21 January 2018

1 reference

Avian influenza A (H5N1) infection in humans

21 January 2018

1 reference

Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997.

21 January 2018

1 reference

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

21 January 2018

1 reference

Treatment of influenza with neuraminidase inhibitors: virological implications

21 January 2018

1 reference

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

21 January 2018

1 reference

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

21 January 2018

1 reference

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/507552

1 reference

20 June 2017

1 reference